238 related articles for article (PubMed ID: 12458343)
1. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
2. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.
Ohga T; Koike K; Ono M; Makino Y; Itagaki Y; Tanimoto M; Kuwano M; Kohno K
Cancer Res; 1996 Sep; 56(18):4224-8. PubMed ID: 8797596
[TBL] [Abstract][Full Text] [Related]
3. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma.
Oda Y; Sakamoto A; Shinohara N; Ohga T; Uchiumi T; Kohno K; Tsuneyoshi M; Kuwano M; Iwamoto Y
Clin Cancer Res; 1998 Sep; 4(9):2273-7. PubMed ID: 9748149
[TBL] [Abstract][Full Text] [Related]
4. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen.
Ise T; Nagatani G; Imamura T; Kato K; Takano H; Nomoto M; Izumi H; Ohmori H; Okamoto T; Ohga T; Uchiumi T; Kuwano M; Kohno K
Cancer Res; 1999 Jan; 59(2):342-6. PubMed ID: 9927044
[TBL] [Abstract][Full Text] [Related]
5. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells.
Nagatani G; Nomoto M; Takano H; Ise T; Kato K; Imamura T; Izumi H; Makishima K; Kohno K
Cancer Res; 2001 Feb; 61(4):1592-7. PubMed ID: 11245470
[TBL] [Abstract][Full Text] [Related]
7. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer.
Shibahara K; Sugio K; Osaki T; Uchiumi T; Maehara Y; Kohno K; Yasumoto K; Sugimachi K; Kuwano M
Clin Cancer Res; 2001 Oct; 7(10):3151-5. PubMed ID: 11595709
[TBL] [Abstract][Full Text] [Related]
8. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
9. The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells.
Guay D; Garand C; Reddy S; Schmutte C; Lebel M
Cancer Sci; 2008 Apr; 99(4):762-9. PubMed ID: 18307537
[TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanism of the stress induction of MDR1 gene].
Kohno K
Nihon Rinsho; 1997 May; 55(5):1054-8. PubMed ID: 9155152
[TBL] [Abstract][Full Text] [Related]
11. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures.
Guay D; Evoy AA; Paquet E; Garand C; Bachvarova M; Bachvarov D; Lebel M
Int J Biochem Cell Biol; 2008; 40(11):2492-507. PubMed ID: 18571458
[TBL] [Abstract][Full Text] [Related]
12. Nuclear localization of Y-box factor YB1 requires wild-type p53.
Zhang YF; Homer C; Edwards SJ; Hananeia L; Lasham A; Royds J; Sheard P; Braithwaite AW
Oncogene; 2003 May; 22(18):2782-94. PubMed ID: 12743601
[TBL] [Abstract][Full Text] [Related]
13. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
14. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
15. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer.
Huang X; Ushijima K; Komai K; Takemoto Y; Motoshima S; Kamura T; Kohno K
Gynecol Oncol; 2004 May; 93(2):287-91. PubMed ID: 15099935
[TBL] [Abstract][Full Text] [Related]
17. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression.
Oda Y; Ohishi Y; Basaki Y; Kobayashi H; Hirakawa T; Wake N; Ono M; Nishio K; Kuwano M; Tsuneyoshi M
Cancer Sci; 2007 Jul; 98(7):1020-6. PubMed ID: 17459055
[TBL] [Abstract][Full Text] [Related]
19. The pleiotropic functions of the Y-box-binding protein, YB-1.
Kohno K; Izumi H; Uchiumi T; Ashizuka M; Kuwano M
Bioessays; 2003 Jul; 25(7):691-8. PubMed ID: 12815724
[TBL] [Abstract][Full Text] [Related]
20. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
